Study finds 'dramatic' benefit from Pfizer's breast cancer hopeful

Strong Phase II data for Pfizer's ($PFE) dual-kinase blocker for breast cancer has analysts anticipating a "mega-blockbuster" as the drugmaker aims to launch Phase III next year. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.